The United States Patent and Trademark Office (USPTO) held a virtual panel discussion on Thursday, February 23, from 3-4 p.m. ET, on the duty of disclosure and duty of reasonable inquiry. Last July, the USPTO issued a Federal Register notice clarifying these duties, including as to materials or statements material to patentability, or statements made to the USPTO that are inconsistent with statements submitted to the FDA and other governmental agencies.
The panel discussion was moderated by a patent practitioner and the panelists discussed and answered frequently asked questions that the USPTO has received from stakeholders.
- Kimberly Braslow, Patent Director, AstraZeneca & Vice Chair, AIPLA Food and Drug Committee
Panelists from the Office of Patent Legal Administration:
- Robert A. Clarke, Director
- Mary Till, Senior Legal Advisor
- Matthew Sked, Senior Legal Advisor
Panelist from the Office of Enrollment and Discipline:
- Ronald K. Jaicks, Senior Counsel for Disciplinary Investigations
The event was free and open to all.
For more information, check out the USPTO Director's Blog on duty of disclosure and duty of reasonable inquiry.
If you are an individual with a disability and would like to request a reasonable accommodation, please submit your request to the contact information listed above.